ReviewCurrent heart failure reports2017
Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.
Review in Current heart failure reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.European journal of heart failure · 2018Pooled it
- Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.Heart failure reviews · 2025Review
- Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches.International journal of molecular sciences · 2025Review
- Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities.Current heart failure reports · 2024Review
- Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.Clinical microbiology reviews · 2024Review
- Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.Heart failure reviews · 2023Review
- The cardiosplenic axis: the prognostic role of the spleen in heart failure.Heart failure reviews · 2022Review
- Introduction of a new scoring tool to identify clinically stable heart failure patients.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2022Article
- Consensus Transcriptional Landscape of Human End-Stage Heart Failure.Journal of the American Heart Association · 2021Review
- Big Data Approaches in Heart Failure Research.Current heart failure reports · 2020Review
- Non-invasively measured central and peripheral factors of oxygen uptake differ between patients with chronic heart failure and healthy controls.BMC cardiovascular disorders · 2020Article
- Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age.Clinical Medicine Insights. Cardiology · 2018Article
- Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery.Frontiers in cardiovascular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewThe aim of review is to describe the essential role of study designs beyond RCTs in contemporary contest of HF patients giving perspectives on its evolving. The article concludes with concern about the support of observational studies for future randomized clinical trials. RECENT
findingsWith the aging population and spectacular advance in cardiovascular therapy, the clinical syndrome comprising heart failure (HF) is increasingly in complexity of heterogeneity. It remains among the most challenging of clinical syndromes with a magnitude of proposed pathophysiological mechanisms involving the heart and the interplay with cardiac and non-cardiac comorbidities. In this epidemiological scenario, randomized clinical trials are suffering from growing failed treatment, so that a deeper understanding of heterogeneity represents a major unmet need. This field also is greatly in a more nuanced comprehension about the applicability in clinical practice of trials' results derived from well-selected HF population. Thus, we need to reflect on trials failures and the translation of previous trials in clinical practice in order to redirect the future trial intervention.
Indexed as
Identifiers
28434088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.